Director/PDMR Shareholding

RNS Number : 8670L

Avacta Group PLC

02 January 2019

 

02 January 2019

Avacta Group plc

("Avacta", the "Group" or the "Company")

Director's Dealing

Avacta Group plc (AIM: AVCT), the developer of Affimer^® biotherapeutics and reagents, announces that its Chief Financial Officer, Tony Gardiner, has purchased on 31 December 2018 8,196 ordinary shares of 10p each in the Company ("Ordinary Shares") at a price of 30.5 pence per Ordinary Share.

Following this transaction, Tony Gardiner's total beneficial interest in the Company is 8,196 Ordinary Shares, representing less than 0.1% of Avacta's issued share capital. In addition, Tony Gardiner has a joint interest in 150,000 Ordinary Shares; such Ordinary Shares are jointly held by certain Directors individually and Avacta Group Trustee Limited in its capacity as trustee of The Avacta Employees' Share Trust.

- Ends -

For further information from Avacta Group plc, please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer	Tel:  [phone] www.avacta.com
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Sunila de Silva - ECM WG Partners Nigel Birks / Nigel Barnes David Wilson / Claes Spang	Tel:  [phone] www.finncap.com Tel:  [phone] Tel:  [phone] www.wgpartners.co.uk
Turner Pope Investments James Pope / Ben Turner Zyme Communications (Trade and Regional Media) Katie Odgaard Yellow Jersey (Financial Media and IR) Sarah Hollins Harriet Jackson	Tel: [phone] www.turnerpope.com Tel: [phone] www.zymecommunications.com  Tel: [phone] Tel: [phone] [e-mail]

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer^® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer^® technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability.  Affimer^® technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer^® reagents through licensing to developers of life sciences research tools and diagnostics.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Tony Gardiner
2.	Reason for the Notification
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Avacta Group Plc
b)	LEI	2138009U3EG31OPMGH36
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	ordinary shares of 10p
	Identification code	GB00BYYW9G87
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 30.5 pence 8,196
d)	Aggregated information: ·      Aggregated volume ·      Price	See above
e)	Date of the transaction	31 December 2018
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

 

END

 

 

DSHCKDDQFBKDADK